Frontage Holdings Corporation (FGHQF)

Overview

Frontage Holdings Corporation is a contract research organization that specializes in providing a comprehensive range of laboratory and associated services to entities in the pharmaceutical, biotechnology, and agrochemical sectors. With its incorporation in 2018, Frontage Holdings has positioned itself as a vital player in the research and development landscape. The company's headquarters are located in Exton, Pennsylvania, emphasizing its strategic presence in the United States. However, its operations span a global network, extending to the People's Republic of China, Europe, India, Japan, South Korea, and Australia, showcasing its international reach and capabilities. Acting under the umbrella of Hongkong Tigermed Co., Limited, Frontage Holdings leverages its subsidiary status to foster growth and innovation in drug development and analysis.

Products and Services

• Laboratory Testing Services

  Frontage Holdings offers extensive laboratory testing services that encompass method development and validation as well as sample analysis. The company also provides central laboratory services that play a crucial role in the comprehensive support of drug development projects for its clients.

• Chemistry, Manufacturing, and Control (CMC) Services

  This category of services includes expert assistance in drug product development and analysis, as well as the delivery and supply of clinical trial materials. These services are designed to aid pharmaceutical companies at various stages of drug development, ensuring quality and compliance.

• Drug Metabolism and Pharmacokinetic Services

  Understanding the metabolism and pharmacokinetics of new pharmaceuticals is essential for safety and efficacy. Frontage Holdings provides specialized services in this domain to help clients predict drug behavior in the body, facilitating informed decision-making in development phases.

• Early Stage Clinical/Bioequivalence Services

  The company delivers services that are critical in the early stages of clinical research, including studies for bioequivalence and absolute bioavailability. These studies are integral in demonstrating that a new drug is equivalent to an existing drug in terms of absorption and activity.

• Human Radiolabel Studies

  Frontage Holdings offers unique human radiolabel studies that are essential for tracing the distribution and elimination of new drugs within the human body. These studies provide critical data for assessing the potential impact and efficacy of pharmaceutical compounds.

• Chemistry Services

  The provision of custom synthesis services is another area of expertise for Frontage Holdings. This includes the creation of complex chemical substances that require a high level of precision and expertise, supporting the intricate processes of drug discovery and development.